This phase II trial studies how well peginterferon alfa-2b works in treating younger patients with craniopharyngioma that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may interfere with the growth of tumor cells and slow the growth of craniopharyngioma.
Our generous friends at Panda Express will double your impact and match donations - up to $500,000 - through Dec. 31. Make your tax-deductible gift now.